MCID: CRV038
MIFTS: 60

Cervical Squamous Cell Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Cervical Squamous Cell Carcinoma

MalaCards integrated aliases for Cervical Squamous Cell Carcinoma:

Name: Cervical Squamous Cell Carcinoma 11 58 53 14 16 71
Squamous Cell Carcinoma of the Cervix Uteri 11 58
Squamous Cell Carcinoma of Cervix 11

Characteristics:


Prevelance:

Squamous Cell Carcinoma of the Cervix Uteri: 1-9/100000 (Europe, Austria, Belgium, Croatia, Czech Republic, Finland, Germany, Iceland, Ireland, Italy, Latvia, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Switzerland, Netherlands, United Kingdom) 1-5/10000 (Bulgaria, Estonia, Lithuania) 58

Age Of Onset:

Squamous Cell Carcinoma of the Cervix Uteri: Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:3744
NCIt 49 C4028
SNOMED-CT 68 254886006
ICD10 via Orphanet 32 C53.0 C53.1 C53.8
UMLS via Orphanet 72 C0279671
Orphanet 58 ORPHA213767
ICD11 33 1544785014
UMLS 71 C0279671

Summaries for Cervical Squamous Cell Carcinoma

Disease Ontology: 11 A cervix carcinoma that has material basis in squamous cells of the cervix.

MalaCards based summary: Cervical Squamous Cell Carcinoma, also known as squamous cell carcinoma of the cervix uteri, is related to squamous cell carcinoma and suppressor of tumorigenicity 3. An important gene associated with Cervical Squamous Cell Carcinoma is LOC105379013 (Uncharacterized LOC105379013), and among its related pathways/superpathways are Regulation of TP53 Activity and TNFR1 Pathway. The drugs Topotecan and Vinorelbine have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and lymph node, and related phenotypes are endocrine/exocrine gland and cellular

Related Diseases for Cervical Squamous Cell Carcinoma

Diseases related to Cervical Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 32.4 TP73 TP63 TP53 SERPINB3 PIK3CA DAPK1
2 suppressor of tumorigenicity 3 31.9 TP53 CDKN2A
3 cervical cancer 31.5 TYMP TP73 TP63 TP53 SERPINB3 RASSF1
4 adenocarcinoma 31.5 TYMP TP53 TIMP2 PIK3CA MLH1 CDKN2A
5 endocervical adenocarcinoma 31.4 TP53 PIK3CA CDKN2A
6 papilloma 31.4 TP63 TP53 RASSF1 KRT8 CDKN2A
7 cervical adenocarcinoma 31.4 TP53 RASSF1 KRT8 CDKN2A
8 chronic cervicitis 31.2 TP53 CDKN2A
9 mixed cell type cancer 31.0 TP53 PIK3CA MLH1 CDKN2A
10 penile cancer 31.0 TP53 RASSF1 PIK3CA CDKN2A
11 endometrial adenocarcinoma 31.0 TP53 MLH1 CDKN2A
12 human papillomavirus infectious disease 31.0 TP53 PIK3CA CDKN2A
13 carcinosarcoma 30.9 TP53 PIK3CA CDKN2A
14 keratinizing squamous cell carcinoma 30.9 TP53 PIK3CA CDKN2A
15 adenoid cystic carcinoma 30.9 TP63 TP53 RASSF1 PIK3CA DAPK1 CDKN2A
16 anal squamous cell carcinoma 30.8 TP53 PIK3CA CDKN2A
17 basaloid squamous cell carcinoma 30.8 TP53 KRT8 CDKN2A
18 keratoacanthoma 30.8 TP63 TP53 PIK3CA MLH1 KRT8
19 endocervical carcinoma 30.7 TP53 PIK3CA CDKN2A
20 muir-torre syndrome 30.7 TP53 MLH1 CDKN2A
21 ovary adenocarcinoma 30.6 TP53 PIK3CA MLH1 CDKN2A
22 uterine carcinosarcoma 30.6 TP53 PIK3CA MLH1 KRT8
23 breast adenocarcinoma 30.6 TP53 PIK3CA KRT8 CDKN2A
24 transitional cell carcinoma 30.6 TP63 TP53 MMP14 MLH1 DAPK1
25 microinvasive gastric cancer 30.6 XIST TP53 MLH1
26 endometrial cancer 30.4 TYMP TP73 TP53 TIMP2 RASSF1 PIK3CA
27 esophageal cancer 30.3 TYMP TP73 TP53 PIK3CA MMP14 MLH1
28 melanoma 30.1 XIST TP53 TIMP2 RASSF1 PIK3CA MMP14
29 breast cancer 30.1 XIST TYMP TP73 TP63 TP53 TIMP2
30 ovarian cancer 30.0 XIST TYMP TP73 TP53 TIMP2 SKP2
31 hepatocellular carcinoma 29.4 XIST TYMP TP73 TP53 TIMP2 SKP2
32 microinvasive cervical squamous cell carcinoma 11.8
33 cervical verrucous carcinoma 11.3
34 cervical basaloid squamous cell carcinoma 11.3
35 cervical keratinizing squamous cell carcinoma 11.3
36 cervical lymphoepithelioma-like carcinoma 11.3
37 cervical intraepithelial neoplasia 10.8
38 cervix uteri carcinoma in situ 10.5
39 acanthoma 10.5 TP53 PIK3CA CDKN2A
40 esophagus verrucous carcinoma 10.5 TP53 PIK3CA CDKN2A
41 verrucous carcinoma 10.5 TP53 PIK3CA CDKN2A
42 penile benign neoplasm 10.5 TP53 PIK3CA CDKN2A
43 b-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) 10.5 TP53 CDKN2A
44 endometrial squamous cell carcinoma 10.5 TP53 CDKN2A
45 vulva squamous cell carcinoma 10.5 TP53 PIK3CA CDKN2A
46 laryngeal benign neoplasm 10.5 TP53 PIK3CA CDKN2A
47 vulvar disease 10.5 TP53 PIK3CA CDKN2A
48 anus cancer 10.5 TP53 PIK3CA CDKN2A
49 vaginal carcinosarcoma 10.5 TP53 PIK3CA
50 keratosis, seborrheic 10.5 TP53 PIK3CA CDKN2A

Graphical network of the top 20 diseases related to Cervical Squamous Cell Carcinoma:



Diseases related to Cervical Squamous Cell Carcinoma

Symptoms & Phenotypes for Cervical Squamous Cell Carcinoma

MGI Mouse Phenotypes related to Cervical Squamous Cell Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.06 CDKN2A MLH1 MMP14 PIK3CA RASSF1 SERPINB3
2 cellular MP:0005384 9.93 CDKN2A DAPK1 MLH1 MMP14 PIK3CA RASSF1
3 neoplasm MP:0002006 9.91 CDKN2A MLH1 PIK3CA RASSF1 TP53 TP63
4 digestive/alimentary MP:0005381 9.91 CDKN2A KRT8 MLH1 MMP14 PIK3CA RASSF1
5 immune system MP:0005387 9.8 CDKN2A KRT8 MLH1 MMP14 PIK3CA RASSF1
6 reproductive system MP:0005389 9.36 CDKN2A KRT8 MLH1 MMP14 PIK3CA SERPINB3

Drugs & Therapeutics for Cervical Squamous Cell Carcinoma

Drugs for Cervical Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60699 60700
2
Vinorelbine Approved, Investigational Phase 3 71486-22-1 44424639 60780
3
Gemcitabine Approved Phase 3 95058-81-4, 122111-03-9 60750
4
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
5
Tirapazamine Investigational Phase 3 27314-97-2 135413511
6 Antiviral Agents Phase 3
7 Anti-Infective Agents Phase 3
8 Antimetabolites Phase 3
9 topoisomerase I inhibitors Phase 3
10
Epoetin Alfa Phase 3
11 Hematinics Phase 3
12 Chrysarobin Phase 3
13
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
14
Mitomycin Approved Phase 2 50-07-7 5746
15
Ipilimumab Approved Phase 2 477202-00-9
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
17
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
18
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
19
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
20
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
21
Cetuximab Approved Phase 2 205923-56-4
22
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
23
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 11947679 6857599
24
Lenograstim Approved, Investigational Phase 2 135968-09-1
25
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
26
Indomethacin Approved, Investigational Phase 2 53-86-1 3715
27
Zinc cation Approved, Experimental, Investigational Phase 2 7440-66-6, 23713-49-7 32051
28
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
29
Esomeprazole Approved, Investigational, Vet_approved Phase 2 73590-58-6, 119141-88-7 9568614 4594
30
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
31
D-Tyrosine Approved, Experimental, Investigational, Nutraceutical Phase 2 133585-56-5, 60-18-4, 556-02-5 1153 6057
32
Veliparib Investigational Phase 2 912444-00-9 11960529
33 Albumin-Bound Paclitaxel Phase 2
34 Immunoglobulins, Intravenous Phase 2
35 Immunoglobulins Phase 2
36 Immunoglobulin G Phase 2
37 Immune Checkpoint Inhibitors Phase 2
38 Antibodies, Monoclonal Phase 2
39 Antibodies Phase 2
40 Antineoplastic Agents, Immunological Phase 2
41 Immunologic Factors Phase 2
42 Fluorodeoxyglucose F18 Phase 1, Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Endothelial Growth Factors Phase 2
45 Mitogens Phase 2
46 Protein Kinase Inhibitors Phase 2
47 Anti-Bacterial Agents Phase 2
48 Antifungal Agents Phase 2
49 Antibiotics, Antitubercular Phase 2
50 Adjuvants, Immunologic Phase 2

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
2 Phase III Trial to Evaluate the Efficacy of Maintaining Hemoglobin Levels Above 120 g/l With Erythropoietin Versus Above 100 g/l Without Erythropoietin in Anemic Patients Receiving Concurrent Radiation and Cisplatin for Cervical Cancer Completed NCT00017004 Phase 3 Cisplatin
3 A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
4 A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial Completed NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
5 A Phase III Randomized Study of Pretherapeutic Para-aortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy Completed NCT01365156 Phase 3
6 Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial Completed NCT02765919 Phase 3
7 Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) Active, not recruiting NCT01101451 Phase 3 Cisplatin
8 A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer Active, not recruiting NCT02466971 Phase 3 Cisplatin;Triapine
9 A Phase III, Randomized Trial of Weekly Cisplatin and Radiation Versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIIB and IVA Cervical Carcinoma Limited to the Pelvis Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
10 Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma Unknown status NCT03469531 Phase 2 Nimotuzumab;Cisplatin
11 Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial) Unknown status NCT02879214 Phase 2
12 A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA Completed NCT00369122 Phase 2 Cisplatin
13 A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies Completed NCT01693783 Phase 2
14 A Phase 2 Study of Positron Emission Tomography Imaging With [18F]-Fluoromisonidazole (FMISO) and [18F]-Fluorodeoxyglucose (FDG) for Assessment of Tumor Hypoxia in Cervical Cancer Completed NCT00559377 Phase 2
15 A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study Completed NCT02562729 Phase 2
16 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
17 A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma Completed NCT00389974 Phase 2 sunitinib malate
18 A Phase II Evaluation of Cetuximab (Erbitux®, C225, NSC# 714692) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT00499031 Phase 2
19 A Phase II Evaluation Of Docetaxel (NSC #628503) In The Treatment Of Persistent Or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00041093 Phase 2 Docetaxel
20 A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix Completed NCT00031993 Phase 2 erlotinib hydrochloride
21 A Phase II Study of Oxaliplatin in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
22 A Phase II Trial of Bevacizumab (rhuMAB VEGF) (NSC #704865) in the Treatment of Persistent and Recurrent Squamous Cell Carcinoma of the Cervix (Group A) Completed NCT00025233 Phase 2
23 Prospective Evaluation of Pelvic Exenteration in Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
24 A Phase II Evaluation of ABI-007 in the Treatment of Persistent or Recurrent Squamous or Nonsquamous Cell Carcinoma of the Cervix Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
25 A Phase II Study of Temsirolimus (NSC 683864), an mTOR Inhibitor, in Patients With Recurrent, Unresectable, Locally Advanced or Metastatic Carcinoma of the Cervix Completed NCT01026792 Phase 2 Temsirolimus
26 A Phase II Evaluation of ADXS11-001 (NSC 752718) in the Treatment of Persistent or Recurrent Squamous or Non-Squamous Cell Carcinoma of the Cervix Completed NCT01266460 Phase 2
27 A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
28 A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048) Completed NCT01267253 Phase 2 Brivanib Alaninate
29 A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer Completed NCT02921269 Phase 2 Atezolizumab
30 PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX Completed NCT02164461 Phase 1, Phase 2
31 A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma Completed NCT01807546 Phase 2 rigosertib
32 A Phase II Open-Label, Single Arm Pilot Study to Evaluate the Safety and Efficacy of Pembrolizumab for High-Grade Cervical Intraepithelial Neoplasia Recruiting NCT04712851 Phase 2
33 IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer Recruiting NCT04580771 Phase 2 Cisplatin
34 A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3) Recruiting NCT03267680 Phase 2 Cyclophosphamide;Indomethacin;Omeprazole
35 A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors Active, not recruiting NCT03074513 Phase 2 Atezolizumab
36 A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) Withdrawn NCT03834571 Phase 2 Carboplatin;Cisplatin;Paclitaxel
37 A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes Unknown status NCT01295502 Phase 1 Carboplatin;Cisplatin;Paclitaxel
38 A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT02113878 Phase 1 BKM120;Cisplatin
39 A Phase I Trial of Tailored Radiation Therapy With Concomitant Cetuximab (C225, NSC #714692) and Cisplatin (NSC #119875) in the Treatment of Patients With Cervical Cancer Completed NCT00104910 Phase 1 Cisplatin
40 A PHASE I STUDY OF PELVIC RADIATION THERAPY WITH CONCOMITANT WEEKLY CISPLATIN AND TOPOTECAN CHEMOTHERAPY IN PATIENTS WITH CERVICAL CARCINOMA WITHOUT EXTRA-PELVIC METASTASIS Completed NCT00054444 Phase 1 Topotecan Hydrochloride Liposomes;Cisplatin
41 A Phase I Study of Whole Pelvic Radiation Therapy With Concomitant Cisplatin and Gemcitabine Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis Completed NCT00068549 Phase 1 Gemcitabine Hydrochloride;Cisplatin
42 A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix Completed NCT01281852 Phase 1 Cisplatin;Paclitaxel;Veliparib
43 A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes Completed NCT01711515 Phase 1 Cisplatin
44 Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer Recruiting NCT02595879 Phase 1 Cisplatin;Triapine
45 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Recruiting NCT02020707 Phase 1 Nab-paclitaxel
46 Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer Active, not recruiting NCT03452332 Phase 1
47 Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer Active, not recruiting NCT03738228 Phase 1 Atezolizumab;Cisplatin
48 Phase 1B, Open-Label, Dose Escalation and Cohort Expansions Trial of Naptumomab Estafenatox (NAP, ABR-217620) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced or Metastatic Solid Tumors Active, not recruiting NCT03983954 Phase 1
49 The Efficacy and Safety of Tislelizumab Combined With Taxanes and Platinum as Neoadjuvant Therapy for Patients With Local Advanced Cervical Carcinoma, an Open Lable,Single-center, Exploratory Clinical Trial Not yet recruiting NCT05013268 Phase 1 Tislelizumab, paclitaxel/docetaxel, cisplatin/carboplatin
50 A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity. Unknown status NCT04588090

Search NIH Clinical Center for Cervical Squamous Cell Carcinoma

Genetic Tests for Cervical Squamous Cell Carcinoma

Anatomical Context for Cervical Squamous Cell Carcinoma

Organs/tissues related to Cervical Squamous Cell Carcinoma:

MalaCards : Cervix, Uterus, Lymph Node, Endothelial, T Cells, Breast, Lung

Publications for Cervical Squamous Cell Carcinoma

Articles related to Cervical Squamous Cell Carcinoma:

(show top 50) (show all 1705)
# Title Authors PMID Year
1
Usefulness of p16 for differentiating primary pulmonary squamous cell carcinoma from cervical squamous cell carcinoma metastatic to the lung. 53 62
19369633 2009
2
Methylation of the RASSF1A gene promoter in Uigur women with cervical squamous cell carcinoma. 53 62
19366060 2009
3
[Expression of Skp2 in cervical squamous cell carcinoma and precancerous lesions and its correlation with HPV16/18 infection]. 53 62
19094580 2008
4
Coordinate expression of cytokeratin 8 and cytokeratin 17 immunohistochemical staining in cervical intraepithelial neoplasia and cervical squamous cell carcinoma: an immunohistochemical analysis and review of the literature. 53 62
18191996 2008
5
Relationship between decreased expression of squamous cell carcinoma antigen 2 and E-cadherin in primary cervical cancer lesions and lymph node metastasis. 53 62
18097581 2008
6
Hypermethylation and loss of heterozygosity of tumor suppressor genes on chromosome 3p in cervical cancer. 53 62
17467893 2007
7
Gene profiling in Pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. 53 62
17306351 2007
8
Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. 53 62
16884378 2006
9
Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. 53 62
16818688 2006
10
EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. 53 62
16425263 2006
11
Expression of thymidine phosphorylase as an effect prediction factor for uterine cervical squamous cell carcinoma after radiotherapy: an immunohistochemical study. 53 62
16803522 2006
12
[Expression of key cell cycle markers in squamous cell carcinoma of the cervix positive in human papillomavirus: a comparative study between Chinese and Australian populations]. 53 62
16677523 2006
13
Reduced radiosensitivity and increased CD40 expression in cyclophosphamide-resistant subclones established from human cervical squamous cell carcinoma cells. 53 62
16142355 2005
14
Radiation-induced cell death is independent of the apoptotic signals mediated by death-associated protein kinase in human cervical squamous cell carcinoma cells. 53 62
16142356 2005
15
Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. 53 62
15843547 2005
16
Thymidine phosphorylase expression is preserved after radiotherapy in patients with cervical squamous cell carcinoma. 53 62
14614573 2004
17
P63 and EGFR as prognostic predictors in stage IIB radiation-treated cervical squamous cell carcinoma. 53 62
14599865 2003
18
Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. 53 62
12909236 2003
19
Both TPA and SCC-Ag levels are prognostic even in high-risk stage Ib-IIa cervical carcinoma as determined by a stratification analysis. 53 62
11876385 2002
20
Vascular endothelial growth factor expression in progression of cervical cancer: correlation with thymidine phosphorylase expression, angiogenesis, tumor cell proliferation, and apoptosis. 53 62
10810442 2000
21
Expression of topoisomerase II and Ki-67 in cervical carcinoma--clinicopathological study using immunohistochemistry. 53 62
10752690 2000
22
Thymidine phosphorylase expression in tumor stroma of uterine cervical carcinomas: histological features and microvessel density. 53 62
10695991 2000
23
Immunohistochemical and DNA sequencing analysis on human mismatch repair gene MLH1 in cervical squamous cell carcinoma with LOH of this gene. 53 62
10769651 2000
24
Biological implications of growth factors on the mechanism of invasion in gynecological tumor cells. 53 62
10545752 1999
25
Fatty acid synthase (FASN) inhibits the cervical squamous cell carcinoma (CESC) progression through the Akt/mTOR signaling pathway. 62
36375657 2023
26
SOX2 expression in the pathogenesis of premalignant lesions of the uterine cervix: its histo-topographical distribution distinguishes between low- and high-grade CIN. 62
35945296 2022
27
Molecular Analysis of HPV-independent Primary Endometrial Squamous Cell Carcinoma Reveals TP53 and CDKN2A Comutations : A Clinicopathologic Analysis With Re-evaluation of Diagnostic Criteria. 62
36069815 2022
28
The regulation role and diagnostic value of fibrinogen-like protein 1 revealed by pan-cancer analysis. 62
36345363 2022
29
Convolutional Neural Networks for Classifying Cervical Cancer Types Using Histological Images. 62
36474087 2022
30
Racial and Ethnic Disparities in Cervical Cancer Incidence, Survival, and Mortality by Histologic Subtype. 62
36455190 2022
31
Identification of novel genetic and epigenetic regulators of different tissue types of cervical cancer. 62
36184073 2022
32
Projectile vomiting as presentation of duodenal intramural metastasis from cervical cancer. 62
36427973 2022
33
MiR-95-3p acts as a prognostic marker and promotes cervical cancer progression by targeting VCAM1. 62
36467343 2022
34
MiR-99a-5p Constrains Epithelial-Mesenchymal Transition of Cervical Squamous Cell Carcinoma Via Targeting CDC25A/IL6. 62
35532870 2022
35
Pembrolizumab Improves Survival After Resection of Intracardiac Metastatic Cervical Carcinoma. 62
35090858 2022
36
Sequential gene expression analysis of cervical malignant transformation identifies RFC4 as a novel diagnostic and prognostic biomarker. 62
36352434 2022
37
Prognostic significance of ferroptosis pathway gene signature and correlation with macrophage infiltration in cervical squamous cell carcinoma. 62
36183678 2022
38
Curious Case of Superfitial Spreading Cervical Squamocellular Carcinoma with Adnexal Involvement. 62
36422194 2022
39
CXCL10 serves as a potential serum biomarker complementing SCC-Ag for diagnosing cervical squamous cell carcinoma. 62
36207693 2022
40
Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance. 62
36207323 2022
41
Can the combination of DWI and T2WI radiomics improve the diagnostic efficiency of cervical squamous cell carcinoma? 62
35842193 2022
42
Identification and validation of serum tumor-markers based nomogram to predict the prognostic value of patients with cervical adenocarcinoma. 62
36270166 2022
43
RNPS1 functions as an oncogenic splicing factor in cervical cancer cells. 62
36300671 2022
44
Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification. 62
36253777 2022
45
Glycogen synthase kinase-3β inactivation promotes cervical cancer progression, invasion, and drug resistance. 62
34554598 2022
46
Single-Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma. 62
35986392 2022
47
The long-term outcomes of clinical responders to neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer. 62
36269389 2022
48
hsa-mir-133a-2 promotes the proliferation and invasion of cervical cancer cells by targeting the LAMB3-mediated PI3K/ATK pathway. 62
36305754 2022
49
Fyn expression is associated with the response of patients with locally advanced uterine cervical squamous cell carcinoma to neoadjuvant chemotherapy. 62
36157319 2022
50
Radiomic Analysis for Pretreatment Prediction of Recurrence Post-Radiotherapy in Cervical Squamous Cell Carcinoma Cancer. 62
36292034 2022

Variations for Cervical Squamous Cell Carcinoma

Cosmic variations for Cervical Squamous Cell Carcinoma:

8 (show top 50) (show all 907)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM123189243 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.270G>A p.L90= 8:116848969-116848969 10
2 COSM127848324 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.127G>A p.E43K 8:116848969-116848969 10
3 COSM123189233 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.249G>A p.L83= 8:116848948-116848948 10
4 COSM127848316 UTP23 cervix,NS,carcinoma,squamous cell carcinoma c.106G>A p.E36K 8:116848948-116848948 10
5 COSM101184918 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4630C>G p.L1544V 16:2086857-2086857 10
6 COSM90408532 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4906C>G p.L1636V 16:2086857-2086857 10
7 COSM149806850 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4843C>G p.L1615V 16:2086857-2086857 10
8 COSM87033167 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4975C>G p.L1659V 16:2086857-2086857 10
9 COSM151515645 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4900C>G p.L1634V 16:2086857-2086857 10
10 COSM150318236 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 10
11 COSM102623419 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4774C>G p.L1592V 16:2086857-2086857 10
12 COSM151373080 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4969C>G p.L1657V 16:2086857-2086857 10
13 COSM150359241 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4771C>G p.L1591V 16:2086857-2086857 10
14 COSM151750121 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 10
15 COSM110108009 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4666C>G p.L1556V 16:2086857-2086857 10
16 COSM148986154 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4777C>G p.L1593V 16:2086857-2086857 10
17 COSM136621744 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4807C>G p.L1603V 16:2086857-2086857 10
18 COSM150579385 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4768C>G p.L1590V 16:2086857-2086857 10
19 COSM147699343 TSC2 cervix,NS,carcinoma,squamous cell carcinoma c.4846C>G p.L1616V 16:2086857-2086857 10
20 COSM122748443 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.434G>T p.C145F 17:7673790-7673790 10
21 COSM93517877 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 17:7673752-7673752 10
22 COSM144129341 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.242G>T p.S81I 17:7674244-7674244 10
23 COSM143944858 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.109C>T p.R37* 17:7674945-7674945 10
24 COSM144310445 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.700C>T p.R234C 17:7673803-7673803 10
25 COSM121892294 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.434G>T p.C145F 17:7673790-7673790 10
26 COSM143371865 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.469C>T p.R157* 17:7674945-7674945 10
27 COSM145017326 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 10
28 COSM143156696 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.224A>G p.Y75C 17:7674262-7674262 10
29 COSM143157606 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.109C>T p.R37* 17:7674945-7674945 10
30 COSM142566486 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701G>C p.R234P 17:7673802-7673802 10
31 COSM122734408 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.421C>T p.R141C 17:7673803-7673803 10
32 COSM121883974 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.422G>C p.R141P 17:7673802-7673802 10
33 COSM144086975 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.47G>A p.R16H 17:7675088-7675088 10
34 COSM144653059 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.310G>A p.V104M 17:7675185-7675185 10
35 COSM88036027 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 17:7674188-7674188 10
36 COSM145017959 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.700C>T p.R234C 17:7673803-7673803 10
37 COSM143943866 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.59A>G p.H20R 17:7675076-7675076 10
38 COSM143168691 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.353G>T p.C118F 17:7673790-7673790 10
39 COSM121894970 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.452G>A p.R151H 17:7673772-7673772 10
40 COSM142846443 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 17:7675062-7675062 10
41 COSM121875983 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.347G>A p.R116Q 17:7674220-7674220 10
42 COSM143370595 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.407G>A p.R136H 17:7675088-7675088 10
43 COSM143370869 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
44 COSM106069893 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 17:7673772-7673772 10
45 COSM145017657 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 10
46 COSM112308199 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 17:7674244-7674244 10
47 COSM143376130 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.329G>C p.S110T 17:7673814-7673814 10
48 COSM143422228 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.602G>T p.S201I 17:7674244-7674244 10
49 COSM143384418 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.433G>A p.D145N 17:7675062-7675062 10
50 COSM144024948 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.517G>A p.D173N 17:7675062-7675062 10

Copy number variations for Cervical Squamous Cell Carcinoma from CNVD:

6 (show all 38)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 191444 5 1 15100000 Gain PDCD6 Cervical squamous cell carcinoma
2 191466 5 1 18500000 Gain TENT4A Cervical squamous cell carcinoma
3 191467 5 1 18500000 Gain SDHA Cervical squamous cell carcinoma
4 191468 5 1 18500000 Gain SRD5A1 Cervical squamous cell carcinoma
5 191624 5 1 42400000 Gain RPL37 Cervical squamous cell carcinoma
6 191625 5 1 42400000 Gain SKP2 Cervical squamous cell carcinoma
7 191627 5 1 42400000 Gain SLC1A3 Cervical squamous cell carcinoma
8 191642 5 1 4400000 Gain IRX2 Cervical squamous cell carcinoma
9 191643 5 1 4400000 Gain NDUFS6 Cervical squamous cell carcinoma
10 191644 5 1 4400000 Gain TERT Cervical squamous cell carcinoma
11 191646 5 1 4400000 Gain TRIP13 Cervical squamous cell carcinoma
12 191726 5 1 8200000 Gain IRX4 Cervical squamous cell carcinoma
13 195451 5 15100000 18500000 Gain ANKH Cervical squamous cell carcinoma
14 195452 5 15100000 18500000 Gain ZNF622 Cervical squamous cell carcinoma
15 195453 5 15100000 23300000 Gain MYO10 Cervical squamous cell carcinoma
16 195454 5 15100000 29300000 Gain BASP1 Cervical squamous cell carcinoma
17 198725 5 29300000 34400000 Gain DROSHA Cervical squamous cell carcinoma
18 198726 5 29300000 34400000 Gain GOLPH3 Cervical squamous cell carcinoma
19 198727 5 29300000 34400000 Gain MTMR12 Cervical squamous cell carcinoma
20 198728 5 29300000 34400000 Gain SUB1 Cervical squamous cell carcinoma
21 199076 5 34400000 38500000 Gain DNAJC21 Cervical squamous cell carcinoma
22 199078 5 34400000 38500000 Gain LMBRD2 Cervical squamous cell carcinoma
23 199079 5 34400000 38500000 Gain NIPBL Cervical squamous cell carcinoma
24 199080 5 34400000 38500000 Gain RAD1 Cervical squamous cell carcinoma
25 199082 5 34400000 38500000 Gain TARS1 Cervical squamous cell carcinoma
26 199083 5 34400000 38500000 Gain WDR70 Cervical squamous cell carcinoma
27 199384 5 38500000 42400000 Gain NUP155 Cervical squamous cell carcinoma
28 199385 5 38500000 42400000 Gain OXCT1 Cervical squamous cell carcinoma
29 199684 5 42400000 45800000 Gain CCL28 Cervical squamous cell carcinoma
30 199685 5 42400000 45800000 Gain FBXO4 Cervical squamous cell carcinoma
31 199686 5 42400000 45800000 Gain PAIP1 Cervical squamous cell carcinoma
32 199689 5 42400000 47700000 Gain ZNF131 Cervical squamous cell carcinoma
33 199835 5 4400000 6000000 Gain ICE1 Cervical squamous cell carcinoma
34 202451 5 8200000 15100000 Gain CCT5 Cervical squamous cell carcinoma
35 202452 5 8200000 15100000 Gain DAP Cervical squamous cell carcinoma
36 202454 5 8200000 15100000 Gain MARCHF6 Cervical squamous cell carcinoma
37 202462 5 8200000 23300000 Gain ZFYVE16 Cervical squamous cell carcinoma
38 202464 5 8200000 45800000 Gain TTC33 Cervical squamous cell carcinoma

Expression for Cervical Squamous Cell Carcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Cervical Squamous Cell Carcinoma patients vs. healthy controls: 35 (show all 33)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CRNN cornulin Uterus - 5.62 0.000
2 KRT1 keratin 1 Uterus - 5.32 0.000
3 UPK1A uroplakin 1A Uterus - 4.79 0.000
4 MAL mal, T cell differentiation protein Uterus - 4.73 0.000
5 KRT4 keratin 4 Uterus - 4.45 0.000
6 SPRR3 small proline rich protein 3 Uterus - 4.43 0.000
7 DSG1 desmoglein 1 Uterus - 4.27 0.000
8 CDKN2A cyclin dependent kinase inhibitor 2A Uterus + 4.21 0.000
9 CRISP3 cysteine rich secretory protein 3 Uterus - 4.13 0.000
10 CRCT1 cysteine rich C-terminal 1 Uterus - 3.92 0.000
11 SPINK5 serine peptidase inhibitor Kazal type 5 Uterus - 3.67 0.000
12 SLURP1 secreted LY6/PLAUR domain containing 1 Uterus - 3.54 0.000
13 APOC1 apolipoprotein C1 Uterus + 3.53 0.000
14 HOPX HOP homeobox Uterus - 3.51 0.000
15 EDN3 endothelin 3 Uterus - 3.48 0.000
16 FANCI FA complementation group I Uterus + 3.42 0.000
17 SYNGR3 synaptogyrin 3 Uterus + 3.41 0.000
18 CRYAB crystallin alpha B Uterus - 3.39 0.000
19 KRT13 keratin 13 Uterus - 3.35 0.004
20 MCM5 minichromosome maintenance complex component 5 Uterus + 3.31 0.000
21 ALOX12 arachidonate 12-lipoxygenase, 12S type Uterus - 3.26 0.000
22 PPP1R3C protein phosphatase 1 regulatory subunit 3C Uterus - 3.23 0.000
23 SCEL sciellin Uterus - 3.19 0.000
24 NTS neurotensin Uterus + 3.19 0.006
25 NUSAP1 nucleolar and spindle associated protein 1 Uterus + 3.17 0.000
26 IVL involucrin Uterus - 3.14 0.000
27 IL1R2 interleukin 1 receptor type 2 Uterus - 3.14 0.000
28 CFD complement factor D Uterus - 3.13 0.000
29 SOSTDC1 sclerostin domain containing 1 Uterus - 3.08 0.000
30 ESR1 estrogen receptor 1 Uterus - 3.06 0.000
31 PAMR1 peptidase domain containing associated with muscle regeneration 1 Uterus - 3.06 0.000
32 ENDOU endonuclease, poly(U) specific Uterus - 3.04 0.000
33 HOXC6 homeobox C6 Uterus + 3.01 0.000
Search GEO for disease gene expression data for Cervical Squamous Cell Carcinoma.

Pathways for Cervical Squamous Cell Carcinoma

Pathways related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.78 TP73 TP63 TP53 MLH1 CDKN2A
2
Show member pathways
12.75 TP73 TP63 TP53 PIK3CA DAPK1 CDKN2A
3
Show member pathways
12.53 TP53 RASSF1 PIK3CA MLH1 CDKN2A
4 12.5 TP53 RASSF1 PIK3CA MMP14 CDKN2A
5
Show member pathways
12.43 TP73 TP63 TP53 DAPK1 CDKN2A
6 12.1 TP73 TP63 TP53 SKP2 MLH1 CDKN2A
7
Show member pathways
12.04 TP73 TP63 TP53 CDKN2A
8 11.81 TP73 TP63 TP53 MLH1
9 11.76 TP53 MMP14 CDKN2A
10
Show member pathways
11.74 TP73 TP63 TP53
11 11.72 TP73 TP53 PIK3CA
12
Show member pathways
11.66 TP73 TP53 RASSF1 CDKN2A
13 11.49 TP63 TP53 PIK3CA CDKN2A
14 11.35 DAPK1 PIK3CA TP53
15 11.26 TP53 SKP2 RASSF1 CDKN2A
16 10.81 TP53 CDKN2A
17 10.62 TYMP TP53 RASSF1 DAPK1 CDKN2A
18
Show member pathways
10.56 TP73 TP63 TP53 CDKN2A

GO Terms for Cervical Squamous Cell Carcinoma

Biological processes related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.81 TP73 TP63 TP53 RASSF1 MLH1 CDKN2A
2 cellular senescence GO:0090398 9.73 TP63 TP53 CDKN2A
3 intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator GO:0042771 9.43 TP73 TP63 TP53
4 protein tetramerization GO:0051262 9.1 TP73 TP63 TP53

Molecular functions related to Cervical Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MDM2/MDM4 family protein binding GO:0097371 9.1 TP73 TP63 TP53

Sources for Cervical Squamous Cell Carcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....